Immunotherapy Keytruda Exceeds Opdivo in Q2 sales
Shots:
- Keytruda sold $1.67Bn- 90% Y-o-Y- narrowly beating Opdivo’s $1.63Bn in Q2’18
- Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% reduction in death in NSCLC patient vs chemo
- Above combination is showing immense attraction from Physicians despite of pending FDA approval
| Ref: Merck | Image: Forbes
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
